 Home > Active Ingredient News > Blood System > This year's biggest pharmaceutical acquisition: Johnson and Johnson's $6.5 billion all-cash acquisition of Momenta.

This year's biggest pharmaceutical acquisition: Johnson and Johnson's $6.5 billion all-cash acquisition of Momenta.

 Last Update: 2020-10-03
 Source: Internet
 Author: User

Tags

rubeola igg antibody

anti peg antibody

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Johnson and Johnson has reached a final deal with Momenta, the US biotech company, to buy Momenta for $52.50 a share in cash, with a total stake worth $6.5bn.
deal is likely to be completed in the second half of this year.
deal will give Johnson and Johnson access to a combination of Momenta autoimmune disease drugs, including the anti-FcRn antibody nipocalimab, which is currently being developed to treat the rare neuromuscular disease, severe muscle weakness.
FcRn is to help IgG recycle, thereby increasing the concentration of autoantibodies in the blood.
Nipodalimab can reduce the amount of disease-ing autoantibodies in the blood by blocking FcRn's function.
Photo Source: Nipocalimab's Phase 2 study demonstrates its efficacy and tolerance in patients with severe muscle weakness.
the drug was also evaluated in phase 2/3 studies to treat warm antibody autoimmune hemolytic anemia (wAIHA).
nipocalimab treatment wAIHA has recently been awarded the FDA's title of rare pediatric disease, fast-track designation and orphan drug.
, according to Johnson and Johnson, Nipocalimab's future sales will exceed $1 billion.
.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

SULODEXIDE 99% Almost White Powder Dideu-01112 Dideu

CAS No.: 57821-29-1

Pharmacy Grade

$61.76/G EXW

High Quality GMP / FDA Certificated Liraglutide Powder CAS 204656-20-2 Liraglutide

CAS No.: 204656-20-2

Pharmacy Grade

$30.00/G FOB

Heparin sodium 9041-08-1 vials safe delivery

CAS No.: 9041-08-1

Pharmacy Grade

$1/G EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.